Akorn is an important and unique contributor supporting the healthcare response to the COVID-19 crisis. Throughout this challenging time, Akorn continues to manufacture and supply its pharmaceutical products to the hospitals, customers, and patients that depend on them.
Akorn has not experienced any significant disruptions in our supply chain. We are working closely with customers and government agencies to identify specific product needs and we are effectively shifting manufacturing activities to produce critical products to meet those needs.
To protect our employees and maintain effective operations, we implemented a comprehensive preparedness plan that includes taking precautions that enable social distancing, work from home accommodations, and essential personnel limitations.
Akorn's commitment to patients, customers and communities is unwavering and we are working tirelessly to continue to improve patients' lives through the quality, availability and affordability of our products.